Lung cancer immune study: can durvalumab prime the body before surgery?
NCT ID NCT05206812
First seen Jan 27, 2026 · Last updated May 10, 2026 · Updated 21 times
Summary
This phase 2 trial is testing the drug durvalumab in 25 people with operable non-small cell lung cancer to see how it changes the immune system before their tumor is removed. The main goal is to measure how many tumors shrink or have fewer than 10% viable cancer cells after treatment. This study does not aim to cure the disease but to gather important information about immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.